Premium
MMP‐9 Immunoreactivity in Acute Migraine
Author(s) -
Leira Rogelio,
Sobrino Tomás,
RodríguezYáñez Manuel,
Blanco Miguel,
Arias Susana,
Castillo José
Publication year - 2007
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2006.00641.x
Subject(s) - migraine , matrix metalloproteinase , medicine , cardiology , neuroscience , psychology
Objective.—To examine the role of matrix metalloproteinase 9 (MMP‐9) in migraine during headache and asymptomatic periods. Methods.—Thirty‐four patients with migraine with and without aura (according to International Headache Society criteria) were studied. Clinical characteristic of headache were recorded. Blood samples for measurement of MMP‐9 were drawn during headache attacks and during asymptomatic periods in all patients and in 10 healthy controls. Results.—We found higher plasma MMP‐9 levels in migraine patients than in control group (129.3 [78.0–258.9] vs. 49.6 [39.1‐64.3] ng/mL; P < .001). Migrainous patients showed higher MMP‐9 plasma levels during headache attacks than in asymptomatic periods, both in migraine without aura (338.4 [275.1–396.2] vs. 118.2 [75.3–137.5] ng/mL; P < .0001), and migraine with aura (389.3 [273.4–487.1] vs. 139.3 [107.3–191.4] ng/mL; P < .0001). Conclusions.—Our study showed an increased production of MMP‐9 during migraine attacks. These data suggest a possible role of inflammation or blood–brain barrier disruption during the migraine attack.